Targeted drug combo tested to fight tough bladder cancer
NCT ID NCT05564416
Summary
This study aimed to see if a targeted pill (erdafitinib) alone or combined with an immunotherapy drug (atezolizumab) could shrink aggressive bladder tumors before surgery. It was for patients whose cancer had grown into the muscle wall of the bladder and who could not receive the usual strong chemotherapy. The goal was to see if these treatments could better control the disease and improve outcomes compared to standard care. The study was withdrawn before any participants were enrolled.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for STAGE III BLADDER CANCER AJCC V8 are added.
By submitting, you agree to our Terms of use
Conditions
Explore the condition pages connected to this study.